🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 9 of 757 · Phase 3 first, then by program name

  1. APF530

    Heron Therapeutics

    Nausea and Vomiting

    phase 3 small molecule completed

    1 trial

  2. APL-2

    Apellis Europe B.V.

    Geographic Atrophy

    phase 3 small molecule completed

    2 trials

  3. APL-2

    Apellis Europe B.V.

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule completed

    1 trial

  4. APL-2

    Pharma Mar S.A.

    Geographic Atrophy Secondary to Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  5. APL-2, Pegcetacoplan

    Apellis Europe B.V.

    Geographic Atrophy Secondary to Age-related Macular Degeneration

    phase 3 small molecule completed

    1 trial

  6. APL2

    Apellis Europe B.V.

    FSGS

    phase 3 small molecule active

    1 trial

  7. APR-246 + azacitidine

    Aprea Therapeutics

    MDS

    phase 3 small molecule completed

    1 trial

  8. ARALAST NP 60 mg/kg

    Takeda Pharmaceuticals International AG

    Chronic Obstructive Pulmonary Disease

    phase 3 mab terminated

    1 trial

  9. ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine

    Arcturus Therapeutics Holdings

    COVID-19 Vaccines

    phase 3 mab completed

    1 trial

  10. ARCT-2303

    Arcturus Therapeutics Holdings

    COVID-19

    phase 3 mab completed

    1 trial

  11. ARD-101

    Ark Therapeutics

    Hyperphagia

    phase 3 small molecule on hold

    1 trial

  12. ARGX-113

    Argenx

    Primary immune thrombocytopenia

    phase 3 small molecule active

    1 trial

  13. ARGX-113

    Argenx

    Primary Immune Thrombocytopenia

    phase 3 small molecule active

    1 trial

  14. ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion, Vyvgart 1 000 mg solution for injection

    Argenx

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  15. ARO-APOC3 PFS

    Arrowhead Pharmaceuticals Ireland Limited

    Hypertriglyceridemia (HTG)

    phase 3 small molecule active

    1 trial

  16. ARO-APOC3 PFS, ARO-APOC3, 0.9% Normal Saline for injection

    Arrowhead Pharmaceuticals Ireland Limited

    Familial Chylomicronemia Syndrome (FCS)

    phase 3 small molecule active

    1 trial

  17. ARO-APOC3 PFS, Plozasiran Injection Placebo

    Arrowhead Pharmaceuticals Ireland Limited

    Hypertriglyceridemia

    phase 3 small molecule active

    1 trial

  18. ARO-APOC3 PFS, Plozasiran Injection Placebo

    Arrowhead Pharmaceuticals Ireland Limited

    Severe hypertriglyceridemia (SHTG)

    phase 3 small molecule active

    1 trial

  19. ARQ-151 0.3% cream

    Arcutis Biotherapeutics

    Chronic Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  20. ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%

    Arcutis Biotherapeutics

    Atopic Dermatitis Eczema

    phase 3 small molecule completed

    1 trial

  21. ASCIMINIB HYDROCHLORIDE, ASCIMINIB

    Novartis Ophthalmics Europe

    Chronic Myelogenous Leukemia in chronic phase (CML-CP)

    phase 3 small molecule active

    1 trial

  22. ASCs (Cx401, company code)

    Takeda Pharmaceuticals International AG

    Anal Fistula

    phase 3 small molecule completed

    1 trial

  23. ASP8951, Sodium Chloride 0.9% Intravenous Infusion BP

    Astellas Pharma GmbH

    Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

    phase 3 small molecule active

    1 trial

  24. ASP8951, Sodium Chloride 0.9% Intravenous Infusion BP

    Astellas Pharma GmbH

    Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources